Key result
CAMK2D inhibition rescues cardiac dysfunction in mouse models of RBM20-related DCM.
Why the study?
Pathogenic variants in RBM20 lead to an aggressive form of dilated cardiomyopathy with high risk of ventricular arrhythmias.
Genetic or pharmacological inhibition of CAMK2D rescues cardiac dysfunction in RBM20 mouse models, suggesting a potential therapeutic target for this aggressive dilated cardiomyopathy.
May support CAMK2D inhibition as a target in RBM20 cardiomyopathy; leaves open translation from mouse models to patients.
Pathogenic variants in RBM20, which encodes a cardiac splicing factor, lead to an aggressive form of dilated cardiomyopathy with a high risk of ventricular arrhythmias. This study shows that genetic or pharmacological inhibition of CAMK2D, one of the RBM20 splicing targets, rescues cardiac dysfunction in mouse models of RBM20.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question. Genetic or pharmacological inhibition of CAMK2D rescues cardiac dysfunction in mouse models of RBM20-related dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: